Article: AVANT Atherosclerosis Vaccine Raises HDL Levels, Reduces Atherosclerosis in Vaccinated Animals.

Company Plans to Initiate Human Safety Studies of the Investigational Vaccine

This Summer

NEEDHAM, Mass., April 19 /PRNewswire/ -- A novel vaccine approach shows promise for raising high density lipoprotein (HDL) or "good" cholesterol levels, and preventing atherosclerosis, according to preclinical research presented today by scientists from AVANT Immunotherapeutics (Nasdaq: AVAN). Vaccinated animals demonstrated 35% higher blood HDL cholesterol levels and atherosclerotic lesions were reduced by approximately 40% (p

"We are very pleased with these results, which clearly demonstrate the feasibility of our vaccine approach as a novel strategy for ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!